drugset / Trial / NCT06332170
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
Timeline
- Start
- 2024-04-26
- Primary completion
- 2026-05-30
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | HS-20093 | Other / unclassified | — | Intravenous |